0001104659-18-048862.txt : 20180801 0001104659-18-048862.hdr.sgml : 20180801 20180801192145 ACCESSION NUMBER: 0001104659-18-048862 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180730 FILED AS OF DATE: 20180801 DATE AS OF CHANGE: 20180801 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Mirabelli Christopher CENTRAL INDEX KEY: 0001262326 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37990 FILM NUMBER: 18986196 MAIL ADDRESS: STREET 1: 55 CAMBRIDGE PARKWAY STREET 2: SUITE 301 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER NAME: FORMER CONFORMED NAME: MIRAELLI CHRISTOPHER DATE OF NAME CHANGE: 20030904 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: LEAP THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001509745 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 274412575 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617 252 4343 MAIL ADDRESS: STREET 1: 47 THORNDIKE STREET STREET 2: SUITE B1-1 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Dekkun Corp DATE OF NAME CHANGE: 20110107 4 1 a4.xml 4 X0306 4 2018-07-30 0 0001509745 LEAP THERAPEUTICS, INC. LPTX 0001262326 Mirabelli Christopher C/O LEAP THERAPEUTICS, INC. 47 THORNDIKE STREET SUITE B1-1 CAMBRIDGE MA 02141 1 1 1 0 CEO, President and COB Warrant (Right to Buy) 6.085 2018-07-30 4 J 0 21369 0 A 2017-11-14 2024-11-14 Common Stock 21369 21369 I See Footnotes Pro rata distribution from HealthCare Ventures IX, L.P. ("HCV IX") to its limited partner, Nine Capital Partners, LLC. Christopher K. Mirabelli, Douglas E. Onsi and Augustine Lawlor are the Managing Members of Nine Capital Partners, LLC, and as such, beneficially own and share voting and dispositive power with respect to all of the securities owned by Nine Capital Partners, LLC. Dr. Mirabelli disclaims beneficial ownership of these shares except to the extent of his proportionate pecuniary interest in these securities. The reporting person is also (i) a Managing Director of HealthCare Partners IX, LLC, which is the General Partner of HealthCare Partners IX, L.P., which is the General Partner of HCV IX, (ii) a Managing Director of HealthCare Partners VIII, LLC, which is the General Partner of HealthCare Partners VIII, L.P., which is the General Partner of HealthCare Ventures VIII, L.P. ("HCV VIII"), and (iii) a Managing Director of HCV Strategic LLC, which is the General Partner of HealthCare Ventures Strategic Fund, L.P. ("HCV SF"). HCV IX continues to hold 3,573,376 shares of common stock, HCV VIII continues to hold 2,618,406 shares of common stock, and HCV SF continues to hold 343,889 shares of common stock, representing 24.3%, 17.8%, and 2.3%, respectively, and 44.5% in the aggregate, of the outstanding shares of common stock. /s/ Douglas E. Onsi as attorney-in-fact for Christopher Mirabelli 2018-08-01